Literature DB >> 34083343

Cohort profile: indigenous human papillomavirus and oropharyngeal squamous cell carcinoma study - a prospective longitudinal cohort.

Lisa M Jamieson1, Gail Garvey2, Joanne Hedges3, Cathy Leane4, Isaac Hill5, Alex Brown6, Xiangqun Ju7, Sneha Sethi8, David Roder9, Richard M Logan3, Newell Johnson10, Megan Smith11, Annika Antonsson12, Karen Canfell13.   

Abstract

PURPOSE: Our aims are to: (1) estimate prevalence, incidence, clearance and persistence of oral human papillomavirus (HPV) infection among Indigenous Australians; (2) identify risk factors associated with oropharyngeal squamous cell carcinoma (OPSCC)-related HPV types (HPV 16 or 18); (3) develop HPV-related health state valuations and; (4) determine the impact on OPSCC and cervical cancers, and the cost-effectiveness of extending publicly-funded HPV vaccination among Indigenous Australians. PARTICIPANTS: Participants were recruited from February 2018 to January 2019. Twelve-month follow-up occurred from March 2019 to March 2020. Participants provided socio-demographic characteristics, health-related behaviours including tobacco and alcohol use and sexual history. Health state preferences in regard to HPV vaccination, knowledge regarding HPV infection, OPSCC and cervical cancer were collected using a two-stage standard gamble approach. Participants provided saliva samples and DNA for microbial genotyping was extracted. FINDINGS TO DATE: Of the 910 participants who were positive for β-globin at baseline, 35% had any oral HPV infection. The most prevalent HPV types were 13 or 32 (Heck's disease; 23%). The second most prevalent types were associated with OPSCC (HPV 16 or 18; 3.3%). Of the 645 participants who were positive for β-globin at 12-month follow-up, 43% had any HPV infection. Of these, 33% were HPV types 13 or 32 and 2.5% were HPV 16 or 18. Some 588 participants had β-globin positive oral samples at baseline and 12-month follow-up. The prevalence of any oral HPV infection increased from 34% at baseline to 44% at 12-month follow-up; due to increases in HPV types 13 or 32 (20% at baseline and 34% at 12-month follow-up). FUTURE PLANS: Further funding will be sought to continue follow-up of this cohort, and to include (after a full medical history) a thorough clinical examination of the external head and neck; a complete oral examination and examination of the oropharynx. Blood tests for early stage OPSCC will also be undertaken. © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  epidemiology; public health

Year:  2021        PMID: 34083343     DOI: 10.1136/bmjopen-2020-046928

Source DB:  PubMed          Journal:  BMJ Open        ISSN: 2044-6055            Impact factor:   2.692


  3 in total

1.  Assessment of Pain-Related Fear in Indigenous Australian Populations Using the Fear of Pain Questionnaire-9 (FPQ-9).

Authors:  Manasi Murthy Mittinty; Pedro H R Santiago; Lisa Jamieson
Journal:  Int J Environ Res Public Health       Date:  2022-05-20       Impact factor: 4.614

2.  Focal Epithelial Hyperplasia.

Authors:  Simone Kloch Bendtsen; Kathrine Kronberg Jakobsen; Amanda-Louise Fenger Carlander; Christian Grønhøj; Christian von Buchwald
Journal:  Viruses       Date:  2021-08-02       Impact factor: 5.048

3.  The Prevalence of High- and Low-Risk Types of HPV in Patients with Squamous Cell Carcinoma of the Head and Neck, Patients with Chronic Tonsillitis, and Healthy Individuals Living in Poland.

Authors:  Joanna Katarzyna Strzelczyk; Krzysztof Biernacki; Jadwiga Gaździcka; Elżbieta Chełmecka; Katarzyna Miśkiewicz-Orczyk; Natalia Zięba; Janusz Strzelczyk; Maciej Misiołek
Journal:  Diagnostics (Basel)       Date:  2021-11-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.